公开(公告)号：US20140072558A1

公开(公告)日：2014-03-13

申请号：US14009037

申请日：2012-04-03

申请人： Young Woo Park ,  Ki Won Jo ,  Donghee Lee ,  Eun Kyung Lee ,  Seil Jang ,  Chan Woong Park ,  Dong-Jin Kim ,  Hye Nan Kim ,  Yun Jung Park ,  Jae Eun Park ,  Ji Hyun Park ,  Seok Ho Yoo ,  Myeoung Hee Jang

发明人： Young Woo Park ,  Ki Won Jo ,  Donghee Lee ,  Eun Kyung Lee ,  Seil Jang ,  Chan Woong Park ,  Dong-Jin Kim ,  Hye Nan Kim ,  Yun Jung Park ,  Jae Eun Park ,  Ji Hyun Park ,  Seok Ho Yoo ,  Myeoung Hee Jang

IPC分类号： A61K39/395 ,  G01N33/68 ,  A61K38/17

CPC分类号： A61K39/3955 ,  A61K38/1709 ,  A61K38/177 ,  A61K39/39558 ,  C07K14/705 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/485 ,  A61K2300/00

摘要： The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1; fragments of the extracellular soluble domain of DLK1; mutants of the extracellular soluble domain of DLK1; a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient; and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.

摘要翻译： 本发明涉及包含δ-样1同系物（DLK1）细胞外水溶性结构域的激活素受体IIB型（ACVR2B）抑制剂。 更具体地，本发明涉及DLK1的细胞外可溶性结构域; DLK1细胞外可溶性结构域的片段; DLK1细胞外可溶性结构域的突变体; 用于抑制与ACVR2B受体的配体键合的组合物，其包含突变体的片段作为活性成分; 以及用于预防和治疗包含该疾病的疾病的药物组合物。 本发明的组合物竞争性地结合ACVR2B受体并且抑制ACVR2B配体与ACVR2B受体的结合，所述ACVR2B受体抑制与这种配体相关的蛋白质信号，并且将可用于预防和治疗与之相关的疾病。

公开(公告)号：US08785392B2

公开(公告)日：2014-07-22

申请号：US13142818

申请日：2010-04-13

申请人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

发明人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

IPC分类号： A61K38/16 ,  A61K38/17 ,  A61K39/00 ,  C07K14/435 ,  C07K14/705 ,  C07K14/735 ,  C07K16/28 ,  C07K16/00 ,  C07K14/475

CPC分类号： C07K16/00 ,  C07K14/435 ,  C07K14/475 ,  C07K2319/30 ,  Y10S424/809 ,  Y10S530/866

摘要： A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

摘要翻译： 构建了包含DLK1和IgG抗体Fc结构域基因的细胞外可溶性域基因的重组表达载体，并且在293E细胞上表达和纯化DLK1-Fc融合蛋白。 本发明通过确认DLK1-Fc融合蛋白对癌细胞的迁移显着减少并且还计算药代动力学参数，证实了作为抑制癌症转移的药物的功效。 DLK1-Fc融合蛋白具有比非融合蛋白更高的稳定性，显着降低各种癌细胞系的迁移，即使在小浓度下也能提供优异的癌转移抑制作用。 因此，DLK1-Fc融合蛋白可以有效地用作抑制癌症转移的组合物的有效成分。

公开(公告)号：US20130202592A1

公开(公告)日：2013-08-08

申请号：US13142818

申请日：2010-04-13

申请人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

发明人： Young Woo Park ,  Kiwon Jo ,  Donghee Lee ,  Jung Yu ,  Ji Hyun Park ,  Chan-Woong Park ,  Eun Jin Kim ,  Yun Jung Park

IPC分类号： C07K16/00 ,  C07K14/435

CPC分类号： C07K16/00 ,  C07K14/435 ,  C07K14/475 ,  C07K2319/30 ,  Y10S424/809 ,  Y10S530/866

摘要： A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E cell. The invention confirmed the efficacy as a drug for inhibiting cancer metastasis by confirming markedly reduced migration of cancer cells by DLK1-Fc fusion protein and also computing pharmacokinetic parameters. DLK1-Fc fusion protein has relatively higher stability than non-fusion protein, significantly reduces migration of various cancer cell lines, and provides superior cancer metastasis inhibition effect even at small concentration. Accordingly, DLK1-Fc fusion protein can be used efficaciously as an effective ingredient of a composition for inhibiting cancer metastasis.

摘要翻译： 构建了包含DLK1和IgG抗体Fc结构域基因的细胞外可溶性域基因的重组表达载体，并且在293E细胞上表达和纯化DLK1-Fc融合蛋白。 本发明通过确认DLK1-Fc融合蛋白对癌细胞的迁移显着减少并且还计算药代动力学参数，证实了作为抑制癌症转移的药物的功效。 DLK1-Fc融合蛋白具有比非融合蛋白更高的稳定性，显着降低各种癌细胞系的迁移，即使在小浓度下也能提供优异的癌转移抑制作用。 因此，DLK1-Fc融合蛋白可以有效地用作抑制癌症转移的组合物的有效成分。

公开(公告)号：US09617304B2

公开(公告)日：2017-04-11

申请号：US14002600

申请日：2012-03-02

申请人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

发明人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

IPC分类号： C07K7/08 ,  C07K14/00 ,  C07K14/475 ,  A61K38/00

CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/00 ,  C07K14/4753 ,  C07K2319/10

摘要： The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

公开(公告)号：US20140066375A1

公开(公告)日：2014-03-06

申请号：US14002600

申请日：2012-03-02

申请人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

发明人： Young Woo Park ,  Ki Won Jo ,  Kyu Won Cho ,  Ji Hyun Park ,  Soon Sil Hyun ,  Yun Jung Park

IPC分类号： C07K7/08 ,  C07K14/00

CPC分类号： C07K7/08 ,  A61K38/00 ,  C07K14/00 ,  C07K14/4753 ,  C07K2319/10

摘要： The present invention relates to a novel endocytic motif, and in particular, to a fusion polypeptide including the motif represented by an amino acid sequence of SEQ ID NO. 1 and a protein transduction domain, a pharmaceutical composition for preventing or treating cancer including the same, and a method for treating cancer including the step of administering the composition. The present invention shows the effects of suppressing metastasis, infiltration, angiogenesis, and growth of cancer by specifically inhibiting c-Met endocytosis and effectively inhibiting HGF/c-Met signaling pathway associated with metastasis and growth of various types of cancer cells. Therefore, the present invention can be applied to an anticancer agent for various types of cancer.

摘要翻译： 本发明涉及一种新的内吞基序，特别涉及包含由SEQ ID NO：1的氨基酸序列表示的基序的融合多肽。 1和蛋白质转导结构域，用于预防或治疗包括其的癌症的药物组合物，以及治疗癌症的方法，包括施用组合物的步骤。 本发明通过特异性抑制c-Met内吞作用并有效抑制与各种癌细胞的转移和生长相关的HGF / c-Met信号通路，显示抑制癌转移，浸润，血管生成和生长的作用。 因此，本发明可以应用于各种癌症的抗癌剂。

公开(公告)号：US08889881B2

公开(公告)日：2014-11-18

申请号：US13984567

申请日：2012-02-08

申请人： Hae Young Chung ,  Min Hi Park ,  Young Mi Ha ,  Yu Kyeong Han ,  Ji Young Park ,  Yun Jung Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Yu Min Song ,  Hyung Ryong Moon

发明人： Hae Young Chung ,  Min Hi Park ,  Young Mi Ha ,  Yu Kyeong Han ,  Ji Young Park ,  Yun Jung Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Yu Min Song ,  Hyung Ryong Moon

IPC分类号： C07D277/66 ,  A61Q19/02 ,  A61K31/426 ,  C07D235/18 ,  C07D277/06 ,  A61K8/49 ,  A61Q19/06

CPC分类号： A61K8/49 ,  A61K8/4946 ,  A61K8/4986 ,  A61K31/426 ,  A61K2800/78 ,  A61Q19/02 ,  A61Q19/06 ,  C07D235/18 ,  C07D277/06 ,  C07D277/66

摘要： Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

摘要翻译： 提供具有皮肤美白，抗氧化和PPAR活性的新型化合物及其医疗用途，并且该化合物具有抑制酪氨酸酶的皮肤美白活性，因此可用于皮肤美白药物组合物或 化妆品; 具有抗氧化活性，因此可用于预防和治疗皮肤老化; 并具有PPAR活性，特别是PPARα和PPARγ活性，因此可用于有效预防和治疗肥胖，代谢疾病或心血管疾病的药物组合物或保健食品。

公开(公告)号：US20130045153A1

公开(公告)日：2013-02-21

申请号：US13695342

申请日：2011-04-20

申请人： Chun Joong Kim ,  Yun Jung Park ,  Dong Gyu Chang ,  Ji Ho Park ,  Woo Young Yang

发明人： Chun Joong Kim ,  Yun Jung Park ,  Dong Gyu Chang ,  Ji Ho Park ,  Woo Young Yang

IPC分类号： C01B25/45 ,  B82Y40/00 ,  B82Y30/00

CPC分类号： H01M4/5825 ,  B01J8/10 ,  C01B25/45 ,  C01P2002/72 ,  C01P2004/04 ,  C01P2004/60

摘要： Disclosed is a method for manufacturing a lithium transition metal phosphate. The disclosed method for manufacturing a lithium transition metal phosphate comprises the steps of: injecting reaction materials containing lithium, a transition metal, and a phosphate, into a reactor, and mixing the raw materials at the molecular level in the reactor; and allowing the reaction materials to chemically react in the reactor so as to cause nucleation.

摘要翻译： 公开了一种锂过渡金属磷酸盐的制造方法。 所公开的锂过渡金属磷酸盐的制造方法包括以下步骤：将含有锂，过渡金属和磷酸盐的反应材料注入反应器中，并将反应器中分子水平的原料混合; 并使反应物料在反应器中发生化学反应，从而引起成核。

公开(公告)号：US20140023603A1

公开(公告)日：2014-01-23

申请号：US13984573

申请日：2012-02-08

申请人： Hae Young Chung ,  Hyung Ryong Moon ,  Min Hi Park ,  Young Mi Ha ,  Yun Jung Park ,  Ji Young Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Kyung Jin Lee

发明人： Hae Young Chung ,  Hyung Ryong Moon ,  Min Hi Park ,  Young Mi Ha ,  Yun Jung Park ,  Ji Young Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Kyung Jin Lee

IPC分类号： A61K8/49 ,  A61Q19/02

CPC分类号： C07D263/42 ,  A61K8/49 ,  A61K8/4913 ,  A61K8/4946 ,  A61K8/4953 ,  A61Q19/02 ,  A61Q19/04 ,  A61Q19/08 ,  C07D207/18 ,  C07D207/448 ,  C07D233/96 ,  C07D239/62 ,  C07D277/34

摘要： Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

公开(公告)号：US09216148B2

公开(公告)日：2015-12-22

申请号：US13984573

申请日：2012-02-08

申请人： Hae Young Chung ,  Hyung Ryong Moon ,  Min Hi Park ,  Young Mi Ha ,  Yun Jung Park ,  Ji Young Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Kyung Jin Lee

发明人： Hae Young Chung ,  Hyung Ryong Moon ,  Min Hi Park ,  Young Mi Ha ,  Yun Jung Park ,  Ji Young Park ,  Jin Ah Kim ,  Ji Yeon Lee ,  Kyung Jin Lee

IPC分类号： A61K8/49 ,  A61Q19/02 ,  A61Q19/08 ,  C07D277/34

CPC分类号： C07D263/42 ,  A61K8/49 ,  A61K8/4913 ,  A61K8/4946 ,  A61K8/4953 ,  A61Q19/02 ,  A61Q19/04 ,  A61Q19/08 ,  C07D207/18 ,  C07D207/448 ,  C07D233/96 ,  C07D239/62 ,  C07D277/34

摘要： Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

摘要翻译： 提供具有皮肤美白，抗氧化和PPAR活性的新型化合物及其医疗用途，并且该化合物具有抑制酪氨酸酶的皮肤美白活性，因此可用于皮肤美白药物组合物或 化妆品; 具有抗氧化活性，因此可用于预防和治疗皮肤老化; 并具有PPAR活性，特别是PPARα和PPARγ活性，因此可用于有效预防和治疗肥胖，代谢疾病或心血管疾病的药物组合物或保健食品。

公开(公告)号：US20120141360A1

公开(公告)日：2012-06-07

申请号：US13389502

申请日：2010-08-09

申请人： Yun Jung Park ,  Dong Gyu Chang ,  Chun Joong Kim ,  Ji Ho Park ,  Woo Young Yang

发明人： Yun Jung Park ,  Dong Gyu Chang ,  Chun Joong Kim ,  Ji Ho Park ,  Woo Young Yang

IPC分类号： C01D15/02 ,  B82B1/00 ,  B82B3/00

CPC分类号： C01G23/005 ,  C01P2002/72 ,  C01P2004/04 ,  C01P2006/40 ,  H01M4/485

摘要： A method of preparing lithium titanate nanoparticles, the method including: feeding reactants including lithium and titanium into a reactor, followed by mixing the reactants in the reactor at a molecular level; and generating a crystal nucleus by chemically reacting the reactants in the reactor.

摘要翻译： 一种制备钛酸锂纳米颗粒的方法，该方法包括：将包含锂和钛的反应物进料到反应器中，然后在反应器中以分子水平混合反应物; 并通过使反应物中的反应物发生化学反应而产生晶核。